Newsroom Stay up to date with what’s happening at ONO PHARMA USA. Breadcrumb Newsroom Ono Pharmaceutical Co., Ltd. Acquires Multiple Research-Stage Oncology Programs from KSQ TherapeuticsLicensingJanuary 25, 2023 Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2022SustainabilityDecember 27, 2022 Ono Pharmaceutical Co., Ltd. Selected for the DJSI World Index and DJSI Asia Pacific Index for Three Straight YearsSustainabilityDecember 27, 2022 Ono Pharmaceutical Co., Ltd. and Equillium Announce Exclusive Option and Asset Purchase Agreement for the Development and Commercialization of ItolizumabLicensingDecember 6, 2022 Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial ResultsCompanyOctober 31, 2022 ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.CompanyAugust 31, 2022 ONO PHARMA USA Initiated Phase 1 Study of ONO-7018, a MALT1 Inhibitor,in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.R & DAugust 29, 2022 Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial ResultsCompanyAugust 1, 2022 Ono Pharmaceutical Co., Ltd. Announced 2021 Full Year Financial ResultsCompanyMay 11, 2022 Ono Pharmaceutical Co., Ltd. Announced 2021 3Q Financial ResultsCompanyJanuary 31, 2022 Pagination First page « First Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Page 5 Next page › Last page Last »